PRFX
PainReform Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$862K
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRFX vs ACRS
Revenue, margins, valuation, and 5-year total return — side by side.
ACRS
Aclaris Therapeutics, Inc.
Medical - Diagnostics & Research
Market Cap$586M
5Y Perf.+89.1%
PRFX vs ACRS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRFX | ACRS |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Diagnostics & Research |
| Market Cap | $862K | $586M |
| Revenue (TTM) | $0.00 | $8M |
| Net Income (TTM) | $-4M | $-65M |
| Gross Margin | — | 73.3% |
| Operating Margin | — | -9.8% |
| Total Debt | $45K | $0.00 |
| Cash & Equiv. | $4M | $20M |
PRFX vs ACRS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRFX
ACRS
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| PainReform Ltd. (PRFX) | 100 | 0.1 | -99.9% |
| Aclaris Therapeutic… (ACRS) | 100 | 189.1 | +89.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRFX vs ACRS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRFX leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Aclaris Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PRFX
PainReform Ltd.
The Growth Play
PRFX carries the broadest edge in this set and is the clearest fit for growth exposure.
- EPS growth 81.2%
- 77.9% revenue growth vs ACRS's -58.2%
- 1.9% margin vs ACRS's -8.3%
Best for: growth exposure
ACRS
Aclaris Therapeutics, Inc.
The Income Pick
ACRS is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.30
- -76.3% 10Y total return vs PRFX's -99.9%
- Lower volatility, beta 0.30, current ratio 5.28x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRFX | 77.9% revenue growth vs ACRS's -58.2% |
| Quality / Margins | PRFX | 1.9% margin vs ACRS's -8.3% |
| Stability / Safety | ACRS | Beta 0.30 vs PRFX's 1.73 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ACRS | +288.8% vs PRFX's -82.1% |
| Efficiency (ROA) | PRFX | -36.6% ROA vs ACRS's -40.5% |
PRFX vs ACRS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
PRFX vs ACRS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACRSLAGGINGPRFX
PRFXPainReform Ltd.
1leads
ACRSAclaris Therapeutics,…
3leads
6 Total Categories
CATEGORYLEADERvs PRFXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRFX1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACRS4/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ACRS6/6
Risk & VolatilityBeta, volatility, and downside exposure
ACRS2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRFX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ACRS and PRFX operate at a comparable scale, with $8M and $0 in trailing revenue.
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $8M |
| EBITDAEarnings before interest/tax | -$4M | -$76M |
| Net IncomeAfter-tax profit | -$4M | -$65M |
| Free Cash FlowCash after capex | -$6M | -$47M |
| Gross MarginGross profit ÷ Revenue | — | +73.3% |
| Operating MarginEBIT ÷ Revenue | — | -9.8% |
| Net MarginNet income ÷ Revenue | — | -8.3% |
| FCF MarginFCF ÷ Revenue | — | -6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -85.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +98.9% | +84.2% |
PRFX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — PRFX and ACRS each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| Market CapShares × price | $861,734 | $586M |
| Enterprise ValueMkt cap + debt − cash | -$3M | $566M |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -9.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 74.83x |
| Price / BookPrice ÷ Book value/share | 0.47x | 5.78x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — PRFX and ACRS each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ACRS leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
PRFX delivers a -48.4% return on equity — every $100 of shareholder capital generates $-48 in annual profit, vs $-63 for ACRS. On the Piotroski fundamental quality scale (0–9), ACRS scores 3/9 vs PRFX's 1/9, reflecting mixed financial health.
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -48.4% | -63.0% |
| ROA (TTM)Return on assets | -36.6% | -40.5% |
| ROICReturn on invested capital | — | -53.5% |
| ROCEReturn on capital employed | -3.1% | -47.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.02x | — |
| Net DebtTotal debt minus cash | -$4M | -$20M |
| Cash & Equiv.Liquid assets | $4M | $20M |
| Total DebtShort + long-term debt | $45,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -1048.07x | — |
ACRS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ACRS leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ACRS five years ago would be worth $2,118 today (with dividends reinvested), compared to $23 for PRFX. Over the past 12 months, ACRS leads with a +288.8% total return vs PRFX's -82.1%. The 3-year compound annual growth rate (CAGR) favors ACRS at -16.7% vs PRFX's -78.7% — a key indicator of consistent wealth creation.
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | +68.8% |
| 1-Year ReturnPast 12 months | -82.1% | +288.8% |
| 3-Year ReturnCumulative with dividends | -99.0% | -42.1% |
| 5-Year ReturnCumulative with dividends | -99.8% | -78.8% |
| 10-Year ReturnCumulative with dividends | -99.9% | -76.3% |
| CAGR (3Y)Annualised 3-year return | -78.7% | -16.7% |
ACRS leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
ACRS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ACRS is the less volatile stock with a 0.30 beta — it tends to amplify market swings less than PRFX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACRS currently trades 99.4% from its 52-week high vs PRFX's 10.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 0.30x |
| 52-Week HighHighest price in past year | $17.95 | $4.89 |
| 52-Week LowLowest price in past year | $0.77 | $1.16 |
| % of 52W HighCurrent price vs 52-week peak | +10.6% | +99.4% |
| RSI (14)Momentum oscillator 0–100 | 35.0 | 66.0 |
| Avg Volume (50D)Average daily shares traded | 622K | 1.9M |
ACRS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PRFXPainReform Ltd. | ACRSAclaris Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $10.00 |
| # AnalystsCovering analysts | — | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACRS leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). PRFX leads in 1 (Income & Cash Flow). 1 tied.
Best OverallAclaris Therapeutics, Inc. (ACRS)Leads 3 of 6 categories
Loading custom metrics...
PRFX vs ACRS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRFX or ACRS a better buy right now?
Analysts rate Aclaris Therapeutics, Inc.
(ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRFX or ACRS?
Over the past 5 years, Aclaris Therapeutics, Inc.
(ACRS) delivered a total return of -78. 8%, compared to -99. 8% for PainReform Ltd. (PRFX). Over 10 years, the gap is even starker: ACRS returned -76. 3% versus PRFX's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRFX or ACRS?
By beta (market sensitivity over 5 years), Aclaris Therapeutics, Inc.
(ACRS) is the lower-risk stock at 0. 30β versus PainReform Ltd. 's 1. 73β — meaning PRFX is approximately 471% more volatile than ACRS relative to the S&P 500.
04Which is growing faster — PRFX or ACRS?
On earnings-per-share growth, the picture is similar: PainReform Ltd.
grew EPS 81. 2% year-over-year, compared to 69. 0% for Aclaris Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PRFX or ACRS?
PainReform Ltd.
(PRFX) is the more profitable company, earning 0. 0% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRFX leads at 0. 0% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — ACRS leads at 73. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PRFX or ACRS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRFX or ACRS better for a retirement portfolio?
For long-horizon retirement investors, Aclaris Therapeutics, Inc.
(ACRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 30)). PainReform Ltd. (PRFX) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACRS: -76. 3%, PRFX: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRFX and ACRS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.